Trial · NCT01703208
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With MACE-plus (Confirmed Cardiovascular [CV]-Related Death, Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, or Hospitalization Due to Unstable Angina) | Omarigliptin 25 mg | 66 | -1.14 to -0.90 | Participants | |
| Number of Participants With MACE-plus (Confirmed Cardiovascular [CV]-Related Death, Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, or Hospitalization Due to Unstable Angina) | Placebo | 70 | -1.20 to -0.96 | Participants | |
| Number of Participants With an Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke) | Omarigliptin 25 mg | 114 | -1.14 to -0.90 | Participants | |
| Number of Participants With an Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke) | Placebo | 114 | -1.20 to -0.96 | Participants | |
| Number of Participants With an Event Per 100 Person-Years for First Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke) | Omarigliptin 25 mg | 2.96 | -1.14 to -0.90 | Participants/100 Person-years | |
| Number of Participants With an Event Per 100 Person-Years for First Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke) | Placebo | 2.97 | -1.20 to -0.96 | Participants/100 Person-years | |
| Change From Baseline in Hemoglobin A1C (A1C) at Week 18 | Omarigliptin 25 mg | -0.58 | 95% Confidence Interval 0.82 | Percent | |
| Change From Baseline in Hemoglobin A1C (A1C) at Week 18 | Placebo | -0.16 | 95% Confidence Interval 0.88 | Percent | |
| Change From Baseline in A1C at Week 18 in a Sub-Study of Participants Taking Insulin (With or Without Metformin) | Omarigliptin 25 mg | -0.50 | 95% Confidence Interval -0.57 to -0.42 | Percentage | |
| Change From Baseline in A1C at Week 18 in a Sub-Study of Participants Taking Insulin (With or Without Metformin) | Placebo | -0.11 | 95% Confidence Interval -0.19 to -0.03 | Percentage | |
| Percentage of Participants Who Experienced at Least One Adverse Event in a Sub-study of Participants Taking Insulin Excluding Data After Background Antihyperglycemic Agent (AHA) Change | Omarigliptin 25 mg | 48.8 | Percentage of participants | ||
| Percentage of Participants Who Experienced at Least One Adverse Event in a Sub-study of Participants Taking Insulin Excluding Data After Background Antihyperglycemic Agent (AHA) Change | Placebo | 49.9 | Percentage of participants | ||
| Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event in a Sub-Study of Participants Taking Insulin Excluding Data After Background AHA Change | Omarigliptin 25 mg | 1.1 | -3.13 to -2.25 | Percentage of participants | |
| Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event in a Sub-Study of Participants Taking Insulin Excluding Data After Background AHA Change | Placebo | 0.8 | -4.18 to -3.29 | Percentage of participants | |
| Number of Participants With an Event of CV-Related Death | Omarigliptin 25 mg | 37 | -40.04 to -31.42 | Participants | |
| Number of Participants With an Event of CV-Related Death | Placebo | 35 | -41.21 to -32.62 | Participants | |
| Number of Participants With an Event Per 100 Person-Years of CV-Related Death | Omarigliptin 25 mg | 0.94 | -40.04 to -31.42 | Participants/100 person-years | |
| Number of Participants With an Event Per 100 Person-Years of CV-Related Death | Placebo | 0.89 | -41.21 to -32.62 | Participants/100 person-years | |
| Number of Participants With an Event of First MI (Fatal and Non-fatal) | Omarigliptin 25 mg | 52 | -40.04 to -31.42 | Participants | |
| Number of Participants With an Event of First MI (Fatal and Non-fatal) | Placebo | 60 | -41.21 to -32.62 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01703208/results